MedTrace Logo

Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy

NCT01019668 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2011-07-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness as well as the detrimental influence of half-dose and half-fluence modification of verteporfin photodynamic therapy (PDT) for the treatment of prolonged unresolved central serous chorioretinopathy (CSCR).

Conditions

  • Central Serous Chorioretinopathy

Interventions

DRUG

Verteporfin PDT, half-dose

half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR

DRUG

verteporfin PDT, half-fluence

half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR

Sponsors & Collaborators

  • Shin Kong Wu Ho-Su Memorial Hospital

    lead OTHER

Principal Investigators

  • Cheng-Kuo Cheng, MD · Shin-Kong Wu Ho-Su Memorial Hospital, School of Medicine, Fu-Jen Catholic University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-12-31
Completion
2011-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01019668 on ClinicalTrials.gov